ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
1,09%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,535
1,67%
Bitcoin
63 329,71
1,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) Actualités

GTHX

G1 Therapeutics (GTHX)

G1 Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GTHX
DateHeureSourceTitreSymboleSociété
01/07/202414h00GlobeNewswire Inc.G1 Therapeutics Added to the Russell 2000® and 3000® IndexesNASDAQ:GTHXG1 Therapeutics Inc
24/06/202412h30GlobeNewswire Inc.G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)NASDAQ:GTHXG1 Therapeutics Inc
14/06/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
14/06/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
05/06/202413h00GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
28/05/202412h30GlobeNewswire Inc.Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)NASDAQ:GTHXG1 Therapeutics Inc
23/05/202423h06GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingNASDAQ:GTHXG1 Therapeutics Inc
22/05/202416h00GlobeNewswire Inc.G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitNASDAQ:GTHXG1 Therapeutics Inc
22/05/202412h30GlobeNewswire Inc.G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesNASDAQ:GTHXG1 Therapeutics Inc
01/05/202412h30GlobeNewswire Inc.G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
01/05/202412h25GlobeNewswire Inc.G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibNASDAQ:GTHXG1 Therapeutics Inc
17/04/202415h00GlobeNewswire Inc.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024NASDAQ:GTHXG1 Therapeutics Inc
04/04/202416h30GlobeNewswire Inc.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
28/02/202412h30GlobeNewswire Inc.G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/02/202414h30GlobeNewswire Inc.G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:GTHXG1 Therapeutics Inc
15/02/202414h30GlobeNewswire Inc.G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024NASDAQ:GTHXG1 Therapeutics Inc
12/02/202422h42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GTHXG1 Therapeutics Inc
12/02/202422h05GlobeNewswire Inc.G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h45GlobeNewswire Inc.G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
03/01/202415h00GlobeNewswire Inc.G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
05/12/202315h26GlobeNewswire Inc.G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer TherapyNASDAQ:GTHXG1 Therapeutics Inc
30/11/202302h37GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumNASDAQ:GTHXG1 Therapeutics Inc
01/11/202321h37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GTHXG1 Therapeutics Inc
01/11/202321h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GTHXG1 Therapeutics Inc
01/11/202311h30GlobeNewswire Inc.G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/10/202313h00GlobeNewswire Inc.Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202314h00GlobeNewswire Inc.G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202313h30GlobeNewswire Inc.G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023NASDAQ:GTHXG1 Therapeutics Inc
16/10/202315h00GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care SymposiumNASDAQ:GTHXG1 Therapeutics Inc
18/09/202313h00GlobeNewswire Inc.Black Diamond Therapeutics Announces CEO TransitionNASDAQ:GTHXG1 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GTHX

Dernières Valeurs Consultées

TSXV
HIS
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés